
Diagonal Bio Investor Relations Material
Latest events
Access the full event backlog
Slides, Transcripts, and Reports from 12,000+ public companies
Latest reports from Diagonal Bio
Access all reports
Diagonal Bio AB operates as a biotechnology company in Sweden. The company is focused on the development of drug candidate for treatment of diabetes and obesity, based on its technology for targeting the GLP-1 receptor. The company also develops small molecules for pharmaceutical and diagnostic purposes. It offers DiabNext, which is in Phase II trial for dibenzo-p-dioxin (DCDX)-induced significant reduction in pulmonary hypertension syndrome (PH). The company is based in Lund, Sweden.
Latest articles
)
James Quincey: Coca-Cola Chairman and CEO
James Quincey has dedicated nearly three decades to The Coca-Cola Company, rising through the ranks to become CEO and Chairman of the company.
11 Mar 2025
)
PepsiCo: From Pepsi and Gatorade to Doritos and Lay's
PepsiCo has grown from a soda company into a global leader in food and beverages, with a portfolio of over 200 brands, including Pepsi, Lay's, and Gatorade.
11 Mar 2025
)
Bob Iger: Disney's Visionary CEO
Bob Iger is a legend in the entertainment industry, known for his visionary leadership and as one of the most influential CEOs in Disney's history.
10 Mar 2025
Ticker symbol
DIABIO
Country
🇸🇪 Sweden